Early Aggressive Therapy in Crohn’s Disease: A Five-Year Milestone
New five-year data from the landmark PROFILE trial, presented at ECCO 2026, provide compelling evidence that the long-term trajectory of Crohn’s disease can be altered. The study compared a “top-down” strategy—initiating biologic therapy with infliximab plus an immunomodulator at diagnosis—against conventional “step-up” care in patients with newly diagnosed, active disease. The extended follow-up confirms that early, effective intervention significantly improves rates of sustained steroid-free and surgery-free remission, building on the positive 48-week outcomes previously reported. This research underscores a paradigm shift towards proactive management to modify disease course and prevent complications in chronic inflammatory conditions.
Study Significance: For hepatologists managing complex inflammatory and fibrotic liver diseases like primary sclerosing cholangitis (PSC) or autoimmune hepatitis, this trial reinforces the strategic principle of early, potent intervention. The findings suggest that aggressively targeting inflammation at diagnosis, rather than escalating therapy after complications arise, may yield superior long-term outcomes in preventing fibrosis progression, cirrhosis, and the need for liver transplantation. This data supports a more interventional treatment philosophy that could be applied to analogous chronic liver conditions to improve synthetic liver function and patient prognosis.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
